Optellum Marks a Milestone in Lung Cancer Detection with 250 Clinical Sites and Over 3 Million Cases Analyzed

Optellum's Milestone in Lung Cancer Diagnostics

In a significant advancement for lung cancer care, Optellum has proudly announced its expansion to over 250 clinical sites and the analysis of more than 3 million cases. This achievement is a testament to the company’s dedication to transforming the approach to lung cancer diagnostics and treatment. In recent years, Optellum has been at the forefront of AI-enabled solutions, making strides that empower health systems and clinical teams to better manage high-risk lung nodules.

A Leader in AI-Enabled Diagnostics

Optellum stands out for its innovative solutions that have redefined the landscape of lung cancer detection. The company developed the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for lung cancer risk stratification, known as Lung Cancer Prediction (LCP) AI. This unique system enables clinicians to navigate the complexities of lung nodules effectively, minimizing the uncertainty surrounding indeterminate cases.

The statistics backing Optellum are compelling: as the company helps a patient every 14 seconds, it showcases the immediate impact of its technology on patient care. The integration of advanced AI tools like the Virtual Nodule Clinic (VNC) solution has proven to support guideline-aligned decisions, streamline clinician efficiency, and accelerate the timeline to recommended treatment. This ensures that patients with high-risk nodules receive timely and appropriate care.

Strategic Partnerships Enhance Growth

Optellum’s growth trajectory is not solely about numbers; it is also reflected in the strategic partnerships the company has formed. Collaborations with leading partners such as Bristol Myers Squibb in the US, and Intuitive Surgical in the UK, emphasize Optellum's commitment to integrating AI solutions within clinical frameworks. These partnerships pave the way for comprehensive end-to-end AI-driven lung cancer pathways, promising to enhance the care continuum for lung cancer patients.

The company's influence has already extended to notable health systems including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals. These relationships underline Optellum’s role as a trusted partner in healthcare innovation.

The Future of Lung Cancer Care

Optellum is dedicated to continuous improvement and innovation in lung health. One of the most exciting developments on the horizon is the planned launch of LungDetect in Europe, a tool set to simplify and expedite the identification and characterization of nodules. This expansion is eagerly anticipated by healthcare professionals who seek to enhance patient outcomes.